[Press release – not published yet] AstraZeneca vaccine 79% effective for preventing symptomatic COVID-19

AZD1222 US Phase III trial met primary efficacy endpoint in preventing COVID-19 at interim analysis – AstraZeneca

Commentaries: AstraZeneca vaccine is 79% effective against symptomatic Covid-19, company says – CNN AND AstraZeneca’s Covid-19 vaccine shows better-than-expected efficacy in U.S. trial – STAT AND Expert reaction to press release from AstraZeneca announcing interim data on safety and efficacy from the US trial of the Oxford-AstraZeneca COVID-19 vaccine – Science Media Centre AND AstraZeneca Publishes Reassuring Trial Data, But Vaccine Hesitancy Remains Widespread In European Union – Health Policy Watch